A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

2011 ◽  
Vol 124 (4) ◽  
pp. 965-968 ◽  
Author(s):  
Gonçalo J. L. Bernardes ◽  
Giulio Casi ◽  
Sabrina Trüssel ◽  
Isabelle Hartmann ◽  
Kathrin Schwager ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Vascular Targeting ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

2011 ◽  
Vol 51 (4) ◽  
pp. 941-944 ◽  
Author(s):  
Gonçalo J. L. Bernardes ◽  
Giulio Casi ◽  
Sabrina Trüssel ◽  
Isabelle Hartmann ◽  
Kathrin Schwager ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Vascular Targeting ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy

2019 ◽  
Vol 235 (1) ◽  
pp. 31-64 ◽  
Author(s):  
Sajad Yaghoubi ◽  
Mohammad Hossein Karimi ◽  
Majid Lotfinia ◽  
Tohid Gharibi ◽  
Motahare Mahi‐Birjand ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy

2019 ◽  
Vol 14 (1) ◽  
pp. 93-105 ◽  
Author(s):  
Zhuanglin Li ◽  
Mingxue Wang ◽  
Xuejing Yao ◽  
Wenting Luo ◽  
Yaocheng Qu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Pancreatic Cancer Therapy ◽  
Antibody Drug

scholarly journals Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

Oncotarget ◽  
2020 ◽  
Vol 11 (10) ◽  
pp. 942-942
Author(s):  
David M. Goldenberg ◽  
Thomas M. Cardillo ◽  
Serengulam V. Govindan ◽  
Edmund A. Rossi ◽  
Robert M. Sharkey
Keyword(s):  
Cancer Therapy ◽  
Solid Cancer ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Novel Target ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document